Dianthus Therapeutics DNTH Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's financing cash flow?
- Dianthus Therapeutics (DNTH) reported financing cash flow of $739.41M in Q1 2026.
- How has Dianthus Therapeutics's financing cash flow changed year-over-year?
- Dianthus Therapeutics's financing cash flow increased by 459160.9% year-over-year, from $161K to $739.41M.
- What is the long-term trend for Dianthus Therapeutics's financing cash flow?
- Over 3 years (2021 to 2024), Dianthus Therapeutics's financing cash flow has grown at a 42.2% compound annual growth rate (CAGR), from $89.6M to $257.82M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.